



Delzicol[®] (mesalamine) – First-time generic

- On May 10, 2019, [Teva launched](#) a generic version of Allergan's [Delzicol \(mesalamine\)](#) delayed-release capsules.
- Delzicol is approved for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older, and for the maintenance of remission of ulcerative colitis in adults.
- Mesalamine is also available generically as a [delayed-release 1.2 gm tablet](#), [delayed-release 800 mg tablet](#), [rectal suspension enema](#), and [rectal suppository](#), and a brand extended-release capsule ([Apriso[®]](#)), controlled-release capsule ([Pentasa[®]](#)), and sulfite-free rectal suspension enema ([sfRowasa[®]](#)).
 - The delayed-release 1.2 gm tablet is approved for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.
 - The delayed-release 800 mg tablet is approved for the treatment of moderately active ulcerative colitis in adults.
 - The enema and sfRowasa are approved for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.
 - The rectal suppository is approved in adults for the treatment of mildly to moderately active ulcerative proctitis.
 - Apriso is approved for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
 - Pentasa is approved for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
- According to IMS data as of February 2019, Delzicol had annual sales of approximately \$130 million in the U.S.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.